Nov 5, 6:10 AM ET
Privia Health reported third-quarter 2026 revenue of $657.0 million, up 13.2% from a year earlier, and net income attributable to the company of $13.5 million, up from $6.9 million. The company raised its full-year 2026 guidance, including Adjusted EBITDA of $154 million to $157 million, up from the initial range of $145 million to $155 million. It also agreed to acquire American Choice Healthcare MSSP for approximately $36 million in cash and will exit its Montana partnership effective January 2027.
- Q3 2026 total revenue was $657.0 million, up from $580.4 million; diluted net income per share was $0.10, up from $0.05.
- Updated FY 2026 Adjusted EBITDA guidance is $154 million to $157 million, versus initial guidance of $145 million to $155 million given February 27, 2026.
- Updated FY 2026 GAAP revenue guidance is $2,500 million to $2,550 million, versus initial guidance of $2,350 million to $2,450 million.
- Cash and cash equivalents were $446.3 million at September 30, 2026, with no debt; the company expects at least $520 million in year-end cash including the acquisition.
Read the filing on SEC.gov ↗
Aug 18, 9:03 AM ET
Privia Health Group's board elected Opella Ernest, M.D., a former HCSC executive, as a Class III director effective September 1, 2026, and named her to the Compliance Committee. The change adds a director to the board and carries a $200,000 grant-date value equity award, but the filing does not describe any financial results or operational impact.
- Dr. Ernest was elected by the board on August 12, 2026, effective September 1, 2026.
- She was appointed to the Compliance Committee effective September 1, 2026.
- Non-employee director pay includes an annual cash retainer and restricted stock units with a $200,000 grant-date fair market value.
- Dr. Ernest is currently President, HCSC Markets at Health Care Service Corporation, a role held since 2023.
Read the filing on SEC.gov ↗
Aug 6, 6:23 AM ET
Privia Health Group reported second-quarter 2026 revenue of $632.6 million, up 21.4% from a year earlier, and net income attributable to the company of $9.0 million, up from $2.7 million. The company also raised its full-year 2026 guidance for all key financial metrics, including Adjusted EBITDA of $145 million to $155 million, which indicates improved profitability expectations for shareholders.
- Q2 2026 revenue was $632.6 million, up 21.4% from $521.2 million in Q2 2025.
- Q2 2026 net income attributable to Privia was $9.0 million, or $0.07 per share, versus $2.7 million, or $0.02 per share, a year earlier.
- Q2 2026 Adjusted EBITDA was $37.4 million, up 29.1% from $29.0 million.
- Updated full-year 2026 guidance includes Adjusted EBITDA of $145 million to $155 million and GAAP revenue of $2.35 billion to $2.45 billion.
Read the filing on SEC.gov ↗
Jul 7, 4:09 PM ET
Shawn Morris resigned from Privia Health Group's Board of Directors and its Compliance Committee, effective immediately, on July 6, 2026. The company said the resignation was not due to any disagreement over its operations, policies, or practices.
- Resignation effective July 6, 2026, with immediate effect
- Morris left the Board and the Compliance Committee of the Board
- Company states no disagreement on operations, policies, or practices
- Filing does not name a replacement director
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.